Linical fractures in Asian girls with Cathepsin S Protein site postmenopausal osteoporosis. J Bone Miner Metab. 2006;24(five):414?18. 29. Gorai I, Tanaka Y, Hattori S, Iwaoki Y. Assessment of adherence to therapy of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese ladies. J Bone Miner Metab. 2010;28(two):176?84. 30. Ando H, Otoda T, Ookami H, et al. Dosing time-dependent effect of raloxifene on plasma plasminogen activator inhibitor-1 concentrations in post-menopausal ladies with osteoporosis. Clin Exp Pharmacol Physiol. 2013;40(3):227?32. 31. Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H. Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly females with osteoporosis. Yonsei Med J. 29 2008;49(1):119?28. 32. Gorai I, Hattori S, Tanaka Y, Iwaoki Y. Alfacalcidol-supplemented raloxifene therapy has higher bone-sparing impact than raloxifenealone therapy in postmenopausal Japanese females with osteoporosis or osteopenia. J Bone Miner Metab. 2012;30(3):349?58. 33. Majima T, Komatsu Y, Shimatsu A, et al. Efficacy of combined therapy with raloxifene and alfacalcidol on bone density and biochemical markers of bone turnover in postmenopausal osteoporosis. Endocr J. 2008;55(1):127?34. 34. Hayashi T, Ina K, Maeda M, Nomura H. The effects of selective estrogen receptor modulator treatment following hormone replacement therapy on elderly postmenopausal women with osteoporosis. Nitric Oxide. 2011;24(four):199?03. 35. Morii H, Ohashi Y, Taketani Y, et al. Impact of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: final results from a randomized placebo-controlled trial. Osteoporos Int. 2003;14(ten):793?00.MDS, and Pfizer. MS is an employee of Eli Lilly Japan K.K.; PGC is an employee of Eli Lilly Australia; JAF and RB are staff of Eli Lilly and Enterprise; all are stock stockholders in Eli Lilly and Firm. EH was an employee of Eli Lilly Japan K.K. when this manuscript was developed. EH is at the moment an employee of Amgen Astellas Biopharma K.K.1. [No authors listed]. Who are candidates for CD45 Protein Formulation prevention and treatment for osteoporosis? Osteoporos Int. 1997;7(1):1?. two. Yoshimura N, Muraki S, Oka H, et al. Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese males and girls: the analysis on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab. 2009;27(five):620?28. 3. United Nations. Globe Mortality Report 2011. New York: UN; 2012. Out there from: un.org/esa/population/publications/world mortalityreport2011/World 20Mortality 20Report 202011.pdf. Accessed June 13, 2013. four. Statistics Japan. Current population estimates as of October 1, 2012. Available from: stat.go.jp/english/data/jinsui/2012np/ index.htm. Accessed June 13, 2013. 5. Marshall D, Johnell O, Wedel H. Meta-analysis of how properly measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312(7041):1254?259. 6. Briggs AM, Greig AM, Wark JD. The vertebral fracture cascade in osteoporosis: a evaluation of aetiopathogenesis. Osteoporos Int. 2007; 18(5):575?84. 7. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M. Individuals with prior fractures have an improved threat of future fractures: a summary in the literature and statistical synthesis. J Bone Miner Res. 2000;15(4):721?39. 8. Lindsay R, Burge RT, Strauss DM. One particular year outcomes and fees following a vertebral.